Expression of TLR4 and CD14 in the Central Nervous System (CNS) in a MPTP Mouse Model of Parkinson's-Like Disease

REFERENCES

• K.A. Fitzgerald, D.C. Rowe, and D.T. Golenbock. 2004. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 6 (15):1361–1367.
   PubMedGoogle Scholar
• M.R. Pinsky. 2007. Sepsis and multiple organ failure. Contrib. Nephrol 156:47–63.
   PubMedGoogle Scholar
• E. Jean-Baptiste. 2007. Cellular mechanisms in sepsis. J. Intensive Care Med 22 (2):63–72.
   PubMedGoogle Scholar
• K. Takeda, and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol 17 (1):1–14.
   PubMed Web of Science ®Google Scholar
• A. Poltorak, X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282 (5396):2085–2088.
   PubMed Web of Science ®Google Scholar
• K. Takeda, T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol 21:335–376.
   PubMed Web of Science ®Google Scholar
• L.J. Van Eldik, W.L. Thompson, H. Ralay Ranaivo, H.A. Behanna, and D. Martin Watterson. 2007. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol 82:277–296.
   PubMed Web of Science ®Google Scholar
• V.H. Perry, C. Cunningham, and C. Holmes. 2007. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol 7 (2):161–167.
   PubMed Web of Science ®Google Scholar
• H. Arai, T. Furuya, Y. Mizuno, and H. Mochizuki. 2006. Inflammation and infection in Parkinson's disease. Histol. Histopathol 21 (6):673–678.
   PubMedGoogle Scholar
• P.S. Whitton. 2007. Inflammation as a causative factor in the etiology of Parkinson's disease. Br. J. Pharmacol 150 (8):963–976.
   PubMedGoogle Scholar
• C.W. Olanow, and W.G. Tatton. 1999. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci 22:123–144.
   PubMed Web of Science ®Google Scholar
• P.M. Kidd. 2000. Parkinson's disease as multifactorial oxidative neurodegeneration: Implications for integrative management. Altern. Med. Rev 5 (6):502–29.
   PubMedGoogle Scholar
• S.H. Snyder, and R.J. D'Amato. Predicting Parkinson's disease. NaturE1985 317 (6034):198–199.
   Google Scholar
• J.W. Langston. 1985. MPTP neurotoxicity: An overview and characterization of phases of toxicity. Life Sci 36 (3):201–206.
   PubMedGoogle Scholar
• H.M. Gao, B. Liu, W. Zhang, and J.S. Hong. 2003. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease. FASEB. J 17 (13):1957–1959.
   PubMedGoogle Scholar
• M.M. Bradford. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu. 2002. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem 81 (6):1285–1297.
   PubMedGoogle Scholar
• P.L. McGeer, C. Schwab, A. Parent, and D. Doudet. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol 54 (5):599–5604.
   PubMedGoogle Scholar
• G. Kreutzberg. 1996. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19 (8):312–318.
   PubMed Web of Science ®Google Scholar
• J. Miklossy, D.D. Doudet, C. Schwab, S. Yu, E.G. McGeer, and P.L. McGeer. 2006. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol 197 (2):275–283.
   PubMedGoogle Scholar
• C. Bate, R. Boshuizen, and A. Williams. 2005. Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J. Neuroimmunol 170 (1–2):62–70.
   PubMedGoogle Scholar
• K. Fassbender, S. Walter, S. Kühl, R. Landmann, K. Ishii, T. Bertsch, A.K. Stalder, F. Muehlhauser, Y. Liu, A.J. Ulmer, S. Rivest, A. Lentschat, E. Gulbins, M. Jucker, M. Staufenbiel, K. Brechtel, J. Walter, G. Multhaup, B. Penke, Y. Adachi, T. Hartmann, and K. Beyreuther. 2004. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB. J 18 (1):203–205.
   PubMedGoogle Scholar
• Y. Xia, K. Yamagata, and T.L. Krukoff. 2006. Differential expression of the CD14/TLR4 complex and inflammatory signaling molecules following i.c.v.. administration of LPS. Brain Res 1095 (1):85–95.
   Google Scholar
• D. Milatovic, S. Zaja-Milatovic, K.S. Montine, F.S. Shie, and T.J. Montine. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J. Neuroinflammation 1:20–27.
   PubMedGoogle Scholar
• S. Lacroix, D. Feinstein, and S. Rivest. 1998. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 2004 8 (4):625–640.
   Google Scholar
• N. Laflamme, and S. Rivest. 2001. Toll-like receptor 4: The missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB. J 15 (1):155–163.
   PubMedGoogle Scholar
• J.J. Lin, C.H. Chen, K.C. Yueh, C.Y. Chang, and S.Z. Lin. 2006. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females. Parkinsonism Relat. Disord 12 (1):9–13.
   PubMedGoogle Scholar
• M. Letiembre, W. Hao, Y. Liu, S. Walter, I. Mihaljevic, S. Rivest, T. Hartmann, and K. Fassbender. Innate immune receptor expression in normal brain aging. Neuroscience 2007 146 (1):248–254.
   Google Scholar
• S. Lehnardt, L. Massillon, P. Follett, F.E. Jensen, R. Ratan, P.A. Rosenberg, J.J. Volpe, and T. Vartanian. 2003. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U S A 100 (14):8514–8519.
   PubMedGoogle Scholar
• J.R. Caso, J.M. Pradillo, O. Hurtado, P. Lorenzo, M.A. Moro, and I. Lizasoain. 2007. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 115 (12):1599–1608.
   PubMedGoogle Scholar
• M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett 180 (2):147–150.
   PubMedGoogle Scholar
• E.C. Hirsch, S. Hunot, P. Damier, and B. Faucheux. 1998. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration?. Ann. Neurol 44 (3 Suppl 1):S115–S120.
   Google Scholar